Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
J Immunother Cancer. 2021 Jul;9(7):e002428. doi: 10.1136/jitc-2021-002428.
J Immunother Cancer. 2021.
PMID: 34230109
Free PMC article.